

CLARIS LIFESCIENCES LIMITED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2015

Ahmedabad, India, 13th August 2015: Claris Lifesciences Ltd. (CLL) today announced its Un-Audited Financial Results for the quarter ended 30th June 2015 at its board meeting held at its registered office in Ahmedabad.

Management Representation of the Financial of the Speciality Injectable Business:

(Values in Rupees Mn)

Particulars	Q1FY16 (Apr to Jun 2015)	Previous Quarter (Jan to Mar 2015)	Growth
Net Sales	1,459	1,117	31%
EBITDA	520	404	29%
EBITDA Margin (%age)	36%	36%	
PAT	208	182	14%
PAT Margin (%age)	14%	16%	

Key financial highlights of the Specialty Injectable Business:

- Net Sales for Q1FY15 stood at Rs. 1,459 mn, which has grown by around 31% as compared to the previous quarter.
- EBITDA has grown by 29%; to Rs. 520 mn; over the previous quarter.
- EBITDA margins for the quarter stood at 36%, in line with the margins for the previous quarter.
- Net Profit for the quarter stood at Rs. 208 mn the Profit during the previous quarter stood at Rs. 182 mn, showing a growth of 14% quarter on quarter.
- Assuming this quarter will account for around 25% of the full year sales, the speciality injectables business can be expected to achieve around Rs. 5,800 mn of sales for FY2016.


Region wise Net Sales

(Values in Rupees Mn)

Region	Q1FY16 (Apr to Jun 2015)	Previous Quarter (Jan to Mar 2015)	Growth
USA	534	503	6%
Other Regulated (Ex US) - ORM	347	248	40%
Emerging Markets - EM	578	366	58%
TOTAL	1,459	1,117	31%



- USA sales were in line the previous quarter, showed a modest growth of 6% quarter on quarter and accounted for 36% of the overall sales for the quarter.
- The US sales have largely remained flat due to supplies issues from some of its raw material suppliers, these issues have now been resolved with alternate vendors being identified and added to the ANDAs.
- This quarter saw growth from the Emerging Markets and Other Regulated Markets (ex USA)
- Other Regulated Markets grew at 40% quarter on quarter and accounted for 24% of the overall sales for the quarter.
- Emerging Markets also saw good traction of products during the quarter, with sales increasing to Rs. 578 mn over Rs. 366 mn in the previous quarter, showing a growth of 58% quarter on quarter. Emerging Markets accounted for 40% of the sales during the quarter.



Key financial highlights of the consolidated financials of Claris Lifesciences Ltd.:

(Values in Rupees Mn)

Particulars	Q1FY16 (Apr to Jun 2015)	Q1FY15 (Apr to Jun 2014)	Growth
Net Income	1,919.41	1,563.50	23%
EBITDA	576.86	414.36	39%
EBITDA%	30%	27%	
PAT	202.86	154.78	31%
PAT%	11%	10%	

REVENUE

- The Net Revenue for the quarter stood at Rs. 1,919 mn and it grew by 23% over the same quarter last year.
- During the quarter, pass thought sales of COL accounted for Rs. 419 mn this stood at 24% of the overall net income for the quarter.



EBITDA

- The EBITDA for the quarter grew to Rs. 577 mn and by 39% over the same quarter last year.
- The EBITDA margin for the quarter stood at 30% as compared to the 27% in the same quarter last year; the increased margin is due to increase in own product sales vs the pass through sales of COL.
- As the pass through sales of COL reduces the revenue may reduce, but this would positively affect the margins of the business going forward.

PAT

- The PAT for the quarter grew by 31%; to Rs. 203 mn; over the same quarter last year.
- The PAT margins for the quarter stood at 11% as compared to 10% in the same quarter last year.

###

Disclaimer

This press release may include "forward-looking statements" which involve a number of risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. Claris Lifesciences Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Market information mentioned in the press release is based on IMS Data and/or internal estimates of the company. The press release also contains the carved out financials of the business transferred to Claris Injectables Limited (CIL), these carved out business are management representations and are not audited numbers.

About Claris Lifesciences Limited (CLL)

Claris Lifesciences Limited (BSE Code: 533288) the Company with three segmental revenues, (i) the Speciality Injectables Business which is housed in a wholly owned subsidiary; Claris Injectables Limited, (ii) 20% stake in the Joint Venture with Otsuka and Mitsui for the Infusion Business in India and Emerging Markets, and (iii) the Treasury and Cash management for the funds in the Holding Company.

For more information about the company, log on to: www.clarislifesciences.com

About Claris Injectables Limited (CIL)

Claris Injectables Limited is one of the largest sterile injectables pharmaceutical companies in India. The company manufactures and/or markets products across various therapeutic segments including Anesthesia, Plasma Volume Expanders, Blood Products, Parenteral, Infusion therapy, Anti-infective and Renal Care. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses.

The company has 3 manufacturing plants; at its campus on the out skirts of Ahmedabad. With emphasis on Quality, Technology & Innovation, Claris offers a range of niche technology-driven injectable products across delivery systems such as glass bottles, glass vials & ampoules, and non-PVC/PVC bags. Claris' sterile injectables facilities have been approved by regulatory authorities including USFDA, MHRA (UK), TGA (Australia), and GCC FDCA. The company's manufacturing capabilities have several times received awards from prestigious institutions like Frost & Sullivan and IDMA.

For more information about the company, log on to: www.clarisinj.com

About COL Private Limited (COPL)

COL Private Ltd. (COL) is a Joint Venture between Claris Lifesciences Ltd., India, Otsuka Pharmaceutical Factory, Inc., Japan and Mitsui & Co. Ltd., Japan, for Claris' Infusion Business in India and Emerging Markets. The company primarily manufacture & market products across multiple markets and therapeutic segments. COL, a leader in intravenous nutrition products, is committed to being the best partner of patients and healthcare professionals in the field of clinical nutrition.

The company has products ranging across various therapeutic segments, including infusion therapy, parenteral nutrition, anti-infectives, and plasma volume expanders. We offer injectables in various delivery systems, such as glass and plastic bottles (EURO Head & Nipple Head), ampoules, and non-PVC/PVC bags.





Claris

The company's customer base primarily includes government and private hospitals, aid agencies, and nursing homes.

The company has two state-of-the-art plants at our manufacturing facility located in Ahmedabad, India. One of the facilities has been approved by foreign regulatory authorities including ANVISA (Brasil).

For more information about the company, log on to: www.clarisotsuka.com

